Acetyl-L-Carnitine Supplementation and the Treatment of Depressive Symptoms: A Systematic Review and Meta-Analysis

  title={Acetyl-L-Carnitine Supplementation and the Treatment of Depressive Symptoms: A Systematic Review and Meta-Analysis},
  author={Nicola Veronese and Brendon Stubbs and Marco Solmi and Olesya Ajnakina and Andr{\'e} Ferrer Carvalho and Stefania Maggi},
  journal={Psychosomatic Medicine},
Objective Deficiency of acetyl-L-carnitine (ALC) seems to play a role in the risk of developing depression, indicating a dysregulation of fatty acid transport across the inner membrane of mitochondria. However, data about ALC supplementation in humans are limited. We thus conducted a systematic review and meta-analysis investigating the effect of ALC on depressive symptoms across randomized controlled trials (RCTs). Methods A literature search in major databases, without language restriction… 
Impact of Supplementation and Nutritional Interventions on Pathogenic Processes of Mood Disorders: A Review of the Evidence
This narrative review was conducted using searches of the PubMed/Medline and Google Scholar databases from inception to November 2019. Clinical trials and relevant articles were identified by
Effects of carnitine supplementation on liver aminotransferase enzymes: A systematic review and meta-analysis of randomized controlled clinical trials
Results of the current meta-analysis showed that carnitine supplementation can decrease serum AST and ALT levels significantly, especially when supplementation lasts 3 months or more in patients with elevated serum aminotransferase levels.
The role of acetyl-L-carnitine (LAC) in the treatment of mental disorders
Because LAC is safe to use and has a very good tolerance profile, authors have explored its role in the treatment of many neurological and psychiatric diseases.
L-Carnitine and Acetyl-L-Carnitine: Potential Novel Biomarkers for Major Depressive Disorder
The concentration of LC and ALC in patients with depression was significantly increased in the effective treatment group, and no significant change was observed in the ineffective treatment group.
Role of dietary factors in the prevention and treatment for depression: an umbrella review of meta-analyses of prospective studies
Overall, the associations between dietary factors and depression had been extensively evaluated, but none of them were rated as high quality of evidence, suggesting further studies are likely to change the summary estimates.
[Augmentation with carnicetine for late depression].
The results allow us to recommend the inclusion of carnicetine for the augmentation of antidepressant therapy in elderly patients of the psychiatric hospital to achieve a more rapid and complete therapeutic response and reduce the duration of hospitalization.
Acetyl-l-carnitine deficiency in patients with major depressive disorder
Significance Identifying biological targets in major depressive disorder (MDD) is a critical step for development of effective mechanism-based medications. The epigenetic agent acetyl-l-carnitine
Plasma acetyl-l-carnitine and l-carnitine in major depressive episodes: a case-control study before and after treatment.
A decreased mitochondrial metabolism of l-carnitine into ALC during MDE is restored after a 6-month antidepressant treatment and the magnitude of mitochondrial dysfunction may predict remission after 3 months of antidepressant treatment.
[Prospects of application of acetyl-L-carnitine in neurology and psychiatry (the treatment of polyneuropathy and depressive states)].
Compared with antidepressants efficacy and a minimum of side effects open up wide possibilities of using ALA in the treatment of depression with a low risk of developing NLR.
Potential therapeutic role of carnitine and acetylcarnitine in neurological disorders.
ALCAR emerges as a simple, economical and safe adjuvant option in order to impair the progression of most neurological disorders.